[ad_1]
gEnevieve Edwards, director of external affairs for the MS Society, said, "At present, bureaucracy is a barrier to a better future for people with primary progressive MS.
"These people have no choice and it is simply not true that they are denied access to effective treatment. It does not make sense.
"We are asking NICE, Roche and NHS England to prioritize patients and reach an agreement for the availability of ocrelizumab at an affordable price for the NHS.
"Multiple sclerosis can be painful and often exhausting, and there is now treatment that could help – and even delay the need for a wheelchair by seven years. We need to find a way to make it work.
NHS England said the regulation meant that only one price could be accepted for each drug.
A Nice statement said: "Clinical trial results show that ocrelizumab can slow the worsening of disability in people with this condition, but the size and duration of this effect are uncertain.
"On top of that, the cost-effectiveness estimates of ocrelizumab, compared to the best supportive care, are far superior to those normally seen as an acceptable use of NHS resources."
[ad_2]
Source link
